{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:00:14Z","timestamp":1785546014389,"version":"3.56.0"},"reference-count":45,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T00:00:00Z","timestamp":1515024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The highly attenuated Modified Vaccinia virus Ankara (MVA) lacks most of the known vaccinia virus (VACV) virulence and immune evasion genes. Today MVA can serve as a safety-tested next-generation smallpox vaccine. Yet, we still need to learn about regulatory gene functions preserved in the MVA genome, such as the apoptosis inhibitor genes F1L and E3L. Here, we tested MVA vaccine preparations on the basis of the deletion mutant viruses MVA-\u0394F1L and MVA-\u0394E3L for efficacy against ectromelia virus (ECTV) challenge infections in mice. In non-permissive human tissue culture the MVA deletion mutant viruses produced reduced levels of the VACV envelope antigen B5. Upon mousepox challenge at three weeks after vaccination, MVA-\u0394F1L and MVA-\u0394E3L exhibited reduced protective capacity in comparison to wildtype MVA. Surprisingly, however, all vaccines proved equally protective against a lethal ECTV infection at two days after vaccination. Accordingly, the deletion mutant MVA vaccines induced high levels of virus-specific CD8+ T cells previously shown to be essential for rapidly protective MVA vaccination. These results suggest that inactivation of the anti-apoptotic genes F1L or E3L modulates the protective capacity of MVA vaccination most likely through the induction of distinct orthopoxvirus specific immunity in the absence of these viral regulatory proteins.<\/jats:p>","DOI":"10.3390\/v10010021","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T11:52:47Z","timestamp":1515066767000},"page":"21","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox"],"prefix":"10.3390","volume":"10","author":[{"given":"Asisa","family":"Volz","sequence":"first","affiliation":[{"name":"Lehrstuhl f\u00fcr Virologie, Institut f\u00fcr Infektionsmedizin und Zoonosen, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, 80539 Munich, Germany"},{"name":"Deutsches Zentrum f\u00fcr Infektionsforschung (DZIF), 80539 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Jany","sequence":"additional","affiliation":[{"name":"Lehrstuhl f\u00fcr Virologie, Institut f\u00fcr Infektionsmedizin und Zoonosen, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, 80539 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Freudenstein","sequence":"additional","affiliation":[{"name":"Lehrstuhl f\u00fcr Virologie, Institut f\u00fcr Infektionsmedizin und Zoonosen, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, 80539 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Lantermann","sequence":"additional","affiliation":[{"name":"Division of Virology, Paul-Ehrlich-Institut, 63225 Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Division of Virology, Paul-Ehrlich-Institut, 63225 Langen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Sutter","sequence":"additional","affiliation":[{"name":"Lehrstuhl f\u00fcr Virologie, Institut f\u00fcr Infektionsmedizin und Zoonosen, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, 80539 Munich, Germany"},{"name":"Deutsches Zentrum f\u00fcr Infektionsforschung (DZIF), 80539 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,1,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.vaccine.2013.03.016","article-title":"Protective efficacy of modified vaccinia virus Ankara in preclinical studies","volume":"31","author":"Volz","year":"2013","journal-title":"Vaccine"},{"key":"ref_2","first-page":"187","article-title":"Chapter five\u2014Modified vaccinia virus Ankara: History, value in basic research, and current perspectives for vaccine development","volume":"Volume 97","author":"Kielian","year":"2017","journal-title":"Advances in Virus Research"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"10946","DOI":"10.1128\/JVI.00945-14","article-title":"Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara","volume":"88","author":"Volz","year":"2014","journal-title":"J. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kremer, M., Suezer, Y., Volz, A., Frenz, T., Majzoub, M., Hanschmann, K.-M., Lehmann, M.H., Kalinke, U., and Sutter, G. (2012). Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002557"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1086\/595565","article-title":"Postexposure immunization with modified vaccinia virus Ankara or conventional lister vaccine provides solid protection in a murine model of human smallpox","volume":"199","author":"Paran","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1099\/vir.0.81417-0","article-title":"Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy","volume":"87","author":"Clark","year":"2006","journal-title":"J. Gener. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1099\/vir.0.80646-0","article-title":"Inactivation of the viral interleukin 1\u03b2 receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara","volume":"86","author":"Staib","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11032","DOI":"10.1128\/JVI.00734-07","article-title":"Fowlpox virus encodes a bcl-2 homologue that protects cells from apoptotic death through interaction with the proapoptotic protein bak","volume":"81","author":"Banadyga","year":"2007","journal-title":"J. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1099\/vir.0.82772-0","article-title":"Functional and structural studies of the vaccinia virus virulence factor N1 reveal a bcl-2-like anti-apoptotic protein","volume":"88","author":"Cooray","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Gubser, C., Bergamaschi, D., Hollinshead, M., Lu, X., van Kuppeveld, F.J.M., and Smith, G.L. (2007). A new inhibitor of apoptosis from vaccinia virus and eukaryotes. PLOS Pathog., 3.","DOI":"10.1371\/journal.ppat.0030017"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"39728","DOI":"10.1074\/jbc.M607465200","article-title":"The vaccinia virus protein F1L interacts with bim and inhibits activation of the pro-apoptotic protein bax","volume":"281","author":"Taylor","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11925","DOI":"10.1128\/JVI.00903-07","article-title":"Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines","volume":"81","author":"Gasteiger","year":"2007","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"328ra327","DOI":"10.1126\/scitranslmed.aae0105","article-title":"Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma","volume":"8","author":"Garg","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/mi.2011.3","article-title":"Apoptosis is an innate defense function of macrophages against mycobacterium tuberculosis","volume":"4","author":"Behar","year":"2011","journal-title":"Mucosal Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nri2215","article-title":"How dying cells alert the immune system to danger","volume":"8","author":"Kono","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.abb.2010.11.011","article-title":"The release of high mobility group box 1 in apoptosis is triggered by nucleosomal DNA fragmentation","volume":"506","author":"Yamada","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3390\/v7031429","article-title":"Modulation of SIV and HIV DNA vaccine immunity by fas-fasl signaling","volume":"7","author":"Yan","year":"2015","journal-title":"Viruses"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0168-1702(97)00111-1","article-title":"Apoptosis and host restriction of vaccinia virus in RK13 cells","volume":"52","author":"Chung","year":"1997","journal-title":"Virus Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/sj.cdd.4401718","article-title":"Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis","volume":"13","author":"Fischer","year":"2005","journal-title":"Cell Death Differ."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8394","DOI":"10.1128\/JVI.77.15.8394-8407.2003","article-title":"Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L","volume":"77","author":"Hornemann","year":"2003","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1128\/JVI.79.4.2584-2596.2005","article-title":"Role of viral factor E3L in modified vaccinia virus Ankara infection of human HeLa cells: Regulation of the virus life cycle and identification of differentially expressed host genes","volume":"79","author":"Ludwig","year":"2005","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1099\/vir.0.81623-0","article-title":"Double-stranded RNA-binding protein E3 controls translation of viral intermediate RNA, marking an essential step in the life cycle of modified vaccinia virus Ankara","volume":"87","author":"Ludwig","year":"2006","journal-title":"J. Gen. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"14031","DOI":"10.1128\/JVI.79.22.14031-14043.2005","article-title":"The vaccinia virus F1L protein interacts with the proapoptotic protein bak and inhibits bak activation","volume":"79","author":"Wasilenko","year":"2005","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.coi.2007.05.004","article-title":"Bcl-2-regulated apoptosis: Mechanism and therapeutic potential","volume":"19","author":"Adams","year":"2007","journal-title":"Curr. Opin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"Meyer","year":"1991","journal-title":"J. Gen. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/978-1-61779-876-4_4","article-title":"Easy and efficient protocols for working with recombinant vaccinia virus MVA","volume":"Volume 890","author":"Isaacs","year":"2012","journal-title":"Vaccinia Virus and Poxvirology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1084\/jem.20041912","article-title":"Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines","volume":"201","author":"Tscharke","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1128\/JVI.00427-06","article-title":"Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB\/c mice","volume":"80","author":"Tscharke","year":"2006","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/nm1457","article-title":"Quantification of antibody responses against multiple antigens of the two infectious forms of vaccinia virus provides a benchmark for smallpox vaccination","volume":"12","author":"Putz","year":"2006","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virol.2005.06.043","article-title":"The nonreplicating smallpox candidate vaccines defective vaccinia lister (dvv-l) and modified vaccinia Ankara (MVA) elicit robust long-term protection","volume":"341","author":"Coulibaly","year":"2005","journal-title":"Virology"},{"key":"ref_31","unstructured":"European Medicines Agency (EMEA) (2013). Imvanex: Modifiziertes Vacciniavirus Ankara, Lebend, European Medicines Agency. EMA\/490157\/2013."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Dai, P., Wang, W., Cao, H., Avogadri, F., Dai, L., and Drexler, I. (2014). Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGas\/Sting-mediated cytosolic DNA-sensing pathway. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1003989"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ni1282","article-title":"A toll-like receptor\u2013independent antiviral response induced by double-stranded b-form DNA","volume":"7","author":"Ishii","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1073\/pnas.89.11.4825","article-title":"The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase","volume":"89","author":"Chang","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1006\/viro.1998.9072","article-title":"Vaccinia virus e3l protein is an inhibitor of the interferon (IFN)-induced 2-5a synthetase enzyme","volume":"243","author":"Rivas","year":"1998","journal-title":"Virology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"14396","DOI":"10.1128\/JVI.02082-14","article-title":"Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses","volume":"88","author":"Schweneker","year":"2014","journal-title":"J. Virol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Perdiguero, B., G\u00f3mez, C.E., N\u00e1jera, J.L., Sorzano, C.O.S., Delaloye, J., Gonz\u00e1lez-Sanz, R., Jim\u00e9nez, V., Roger, T., Calandra, T., and Pantaleo, G. (2012). Deletion of the viral anti-apoptotic gene F1L in the HIV\/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048524"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Greenberg, R.N., Hay, C.M., Stapleton, J.T., Marbury, T.C., Wagner, E., Kreitmeir, E., R\u00f6esch, S., von Krempelhuber, A., Young, P., and Nichols, R. (2016). A randomized, double-blind, placebo-controlled phase II trial investigating the safety and immunogenicity of modified vaccinia Ankara smallpox vaccine (mva-bn\u00ae) in 56\u201380-year-old subjects. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157335"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza a H5N1 vaccine: A randomised, double-blind phase 1\/2a clinical trial","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus","volume":"11","author":"Golding","year":"2005","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions","volume":"78","author":"Fogg","year":"2004","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1128\/JVI.79.21.13454-13462.2005","article-title":"Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge","volume":"79","author":"Lustig","year":"2005","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.cell.2016.09.049","article-title":"Cross-neutralizing and protective human antibody specificities to poxvirus infections","volume":"167","author":"Gilchuk","year":"2016","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-065X.2010.00975.x","article-title":"Smallpox vaccines: Targets of protective immunity","volume":"239","author":"Moss","year":"2011","journal-title":"Immunol. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/nbt1215","article-title":"A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus","volume":"24","author":"Moutaftsi","year":"2006","journal-title":"Nat. Biotechnol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/1\/21\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:50:02Z","timestamp":1760194202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/1\/21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,4]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1]]}},"alternative-id":["v10010021"],"URL":"https:\/\/doi.org\/10.3390\/v10010021","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,4]]}}}